Brief: Dermapharm 9M Adjusted EBITDA EUR 243.8 Million
15/11/2023 06:31
Nov 15 (Reuters) - Dermapharm 9M revenue EUR 866.6 million. * 9M adjusted EBITDA margin 28.1%
Recent news on Dermapharm Holding SE
See all newsBrief: Dermapharm Confirms 2026 Forecast
Corrected: Germany's Dermapharm prelim H1 revenue rises, maintains outlook
Brief: Dermapharm Holding - Confirms Full-Year Guidance For 2026
Brief: Dermapharm Spokesperson - Dermapharm Is Engaged In A Constructive Dialogue With The Regulator
Refile: BUZZ-Dermapharm Holding slips after BaFin's audit